Trial Profile

A study of the immune response to vaccination in MS patients treated with alemtuzumab.

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 22 Nov 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DT-poliovirus vaccine (Primary) ; Hib-meningococcal vaccine group C conjugate (Primary) ; Pneumococcal vaccine (Primary)
Indications Diphtheria; Haemophilus infections; Pneumococcal infections; Poliomyelitis; Tetanus
Focus Pharmacodynamics
Acronyms CAM-VAC

Most Recent Events

16 Nov 2011 Planned end date changed from 23 Jun 2013 to 28 Jul 2011 as reported by European Clinical Trials Database.
16 Nov 2011 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
15 Jun 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com